The highest incidence of PML occurs with natalizumab, a monoclonal antibody (mAb) against alpha-4 integrin as a representative of DMT for MS, with an overall global incidence of 3.94 per 1000 patients [9]. Here, ITGA4 is linked to progressive multifocal leukoencephalopathy.